mrx0518
Cell therapyexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2018 (NCT03637803)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 2
- Head and Neck Neoplasms · Phase 1
- Kidney Neoplasms · Phase 1
- Lung Neoplasms · Phase 1
- Melanoma · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 1
- Urethral Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
- Uterine Neoplasms · Phase 1
Mechanism of action
- microbiotaTissue restoration
microbiota tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05107427 | Phase 2 | Dec 31, 2021 | 4DPharma PLC, University of Texas at Houston |
| NCT04193904 | Phase 1 | Dec 31, 2019 | 4DPharma PLC, University of Texas at Houston |
| NCT03934827 | Phase 1 | Apr 10, 2019 | 4DPharma PLC, Imperial College London |
| NCT03637803 | Phase 1 | Oct 31, 2018 | 4DPharma PLC, Merck, University of Texas at Houston |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| 4DPharma PLC | For profit | 4 | 3 | 2 | 2018 |
| University of Texas at Houston | Academic/Hospital | 3 | 0 | 2 | 2018 |
| Imperial College London | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Merck | For profit | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1